Document:

EX-10.13

 Exhibit 10.13 

MANAGEMENT SERVICES AGREEMENT 

This MANAGEMENT SERVICES AGREEMENT (this “Agreement”), dated as of September 22, 2017 (the “Effective
Date”), is by and among Paragon Biosciences, LLC, a Delaware limited liability company (the “Management Company”), Harmony Biosciences, LLC, a Delaware limited liability company (the “Company”), and, solely
with respect to Section 6 herein, Jeffrey S. Aronin (“Aronin”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth Section 9 of this Agreement. 

RECITALS 
 WHEREAS,
the Company is party to that certain License and Commercialization Agreement, dated as of July 28, 2017, with Bioprojet Société Civile de Recherche (the “License Agreement”) with respect to the commercialization
by the Company in the United States and its territories, commonwealths and protectorates (including Puerto Rico) (the “Territory”) of that certain product currently known as
Wakix® (the “Product”); 
 WHEREAS, the Management Company,
together with its Affiliates, provides management, technical, administrative and support services in connection with the registration and commercialization of pharmaceutical products in the Territory; 

WHEREAS, the Company desires to engage the Management Company to provide and arrange certain management, technical, administrative and
support services in connection with the commercialization by the Company of the Product in the Territory and the performance by the Company of its obligations under the License Agreement; and 

WHEREAS, the Company and the Management Company each desires to enter into this Agreement to set forth their mutual understandings and
agreements with respect to the matters set forth herein. 
 AGREEMENTS 

NOW THEREFORE, in consideration of the mutual covenants and promises contained herein and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 

1.    Appointment as Management Company. The Management Company is hereby retained by the Company to
provide certain management and advisory services and other assistance as may be requested by the Company and agreed to by the Management Company from time to time, including, but not limited to, the services described on Schedule A hereto
(the “Management Services”). The Management Company shall use commercially reasonable efforts to provide the Management Services in a manner consistent with industry standards for such Management Services, as employed by
biotechnology and/or pharmaceutical companies that are similarly situated to the Company. The Management Company shall primarily focus on providing senior-level strategic and tactical guidance, oversight, advice and support services with respect to
pharmaceutical-related matters, and assistance to the Company in developing key in-house 

 
capabilities. In this capacity, the Management Company will commit significant management resources to the Company, with the Management Company’s initial leadership team including Jeff
Aronin, Pat Morris, Tim Cunniff, Babar Ghias, Spiro Katerinis and such other individuals deemed appropriate by the Management Company to facilitate the Company’s business plan and objectives. It is the parties’ intent and expectation that
the Management Services will include guidance, oversight, advice and support with respect to key activities necessary or useful to enhance the Company’s ability to obtain regulatory approval for the Product in the Territory. 

2.    Compensation. 

(a)    In exchange for services to be provided by the Management Company hereunder, the Company shall pay
the Management Company, and the Management Company shall be entitled to receive from the Company, a monthly management fee (the “Management Fee”) in the amount of $333,333.33 with respect to each calendar month of the Term prior to
the third (3rd) anniversary of the Effective Date and in the amount of $166,666.66 with respect to each calendar month of the Term following the third (3rd) anniversary of the Effective Date. The Management Fee for the first calendar month of the Term shall be payable within two (2) business days following the Effective Date. Thereafter, the
Management Fee payable with respect to each calendar month shall be paid not later than the fifth day of such calendar month by recurring ACH transfer (established as an automatic feature with the Company’s bank) provided that the Management
Company delivers a written invoice to the Company at least ten (10) days prior to the first day of such calendar month. If the Management Company fails to deliver a written invoice prior to the first day of such calendar month, then the Company
shall pay the Management Fee with respect to a given calendar month no later than thirty (30) days after the receipt of a written invoice from Management Company with respect to the Management Services to be provided (or that were provided) in
such calendar month, by wire transfer of immediately available funds to an account or accounts previously specified in writing by the Management Company. The Management Fee shall be prorated based on the number of days in any partial calendar month
during the Term. If the Management Fee decreases on any day other than the first day of a calendar month, then the Management Fee payable with respect to the applicable calendar month for the period prior to such decrease shall be prorated based on
the number of days in such calendar month prior to such decrease, and the Management Fee payable with respect to such calendar month for the period following such decrease shall be prorated based on the number of days in such calendar month
following such decrease. 
 (b)    In addition to the Management Fee, the Company shall pay to the
Management Company, and the Management Company shall be entitled to receive from the Company, an additional payment in the amount of $4,000,000.00, which shall be paid within one business day following the Effective Date by wire transfer of
immediately available funds to an account or accounts previously specified in writing by the Management Company. 
 Except as contemplated by this
Agreement, the Management Company shall not be entitled to receive from the Company any other compensation or remuneration in consideration for its services to the Company. 

  
 2 

 3.    Expenses. The Management Company shall bear
the cost of its out-of-pocket expenses incurred in connection with the services performed hereunder, and shall not be entitled to reimbursement from the Company. 

4.    Effective Period of Agreement and Amendments. 

(a)    The term of this Agreement (the “Term”) shall begin on the Effective Date and end
on the sixth (6th) anniversary thereof; provided, that the Term may be terminated prior to the expiration thereof (i) by the Management Company at any time for any reason or no reason
by giving the Company written notice of such termination at least one hundred eighty (180) days in advance of such termination date (unless such notice is waived by the Company in its sole discretion, in which case such termination shall be
effective as of the date of such waiver), (ii) by the Company for Cause by giving the Management Company written notice of such termination, (iii) by the Company upon the consummation of an IPO by giving the Management Company written notice of
such termination; provided, however, that if any termination under this subsection (iii) occurs prior to the end of the fourth year following the Effective Date, then within thirty (30) days following such termination the
Company shall pay to the Management Company an amount equal to 100% of all remaining amounts to be paid to the Management Company under this Agreement between the date of such termination and the end of such fourth year, and (iv) by the Company
upon written notice to the Management Company if a Sale of Harmony has been consummated prior the consummation of an IPO; provided, however, that if such Sale of Harmony results in payment to the Investors of an aggregate amount equal
to or greater than the Series A Preferred Return (as defined in the A&R Certificate of Incorporation) (after payment of all costs and expenses incurred by Holdings in connection with such Sale of Harmony, including the payment of amounts payable
to the Management Company pursuant to this Section 4(a)), then within thirty (30) days following such termination the Company shall pay to the Management Company an amount equal to 100% of all remaining amounts to be
paid to the Management Company under this Agreement. 
 (b)    Any amendment to this Agreement shall be
in writing and shall be approved and executed by both the Management Company and the Company; provided, however, that such approval of the Company shall be subject to the authorization and approval of the Board. Sections 5,
6, 7, 11, 12, 15 and 16 of this Agreement shall survive the expiration or termination of the Term. 

5.    Business Opportunity. During the Term and for a period of two (2) years thereafter, if the
Management Company is formally offered an opportunity to pursue a potential transaction to acquire, license or obtain a pharmaceutical product in the Field (as defined in the License Agreement) or to acquire a majority ownership interest in a Person
that sells pharmaceutical products in the Field (but not including a minority investment) that the Management Company reasonably believes is, or may be, within the scope of the business and investment objectives of the Company and would be
beneficial to the business of the Company and that the Management Company desires to pursue (each an “Opportunity”), then the Management Company shall present such Opportunity to the Board. The Board shall determine whether to
pursue any such Opportunity and shall make such determination within a reasonable period of time; provided, that if the Board determines not to pursue any such Opportunity, then the Management Company and its Affiliates will not separately
pursue such Opportunity. 

  
 3 

 6.    Restrictive Covenants. During the Term, the
Management Company and Aronin will have access to the most sensitive and most valuable trade secrets, proprietary information and other confidential information of the Company, including pharmaceutical studies and reports, management reports,
marketing studies, marketing plans, business plans, financial statements, feasibility studies, financial, accounting and statistical data, price and cost information, customer lists, contracts, policies and procedures, internal memoranda, reports
and other materials or records of a proprietary or confidential nature (collectively, “Confidential Information”), which constitute valuable business assets of the Company and its Affiliates, and the use, application or disclosure
of such Confidential Information will cause substantial and possibly irreparable damage to the business and asset value of the Company. Therefore, as an inducement for the Company to enter into this Agreement and to protect the Confidential
Information and other business interests of the Company, Aronin and the Management Company each agree to be bound by the restrictive covenants contained in this Section 6. 

(a)    Confidential Information. After the date of this Agreement, Aronin and the Management Company
will, and, in the case of the Management Company, will cause its Affiliates, directors, managers, officers, equityholders, employees, agents, successors and permitted assigns to, keep confidential and not disclose to any other Person or use for his
or its own benefit, as applicable, or the benefit of any other Person any Confidential Information; provided, however, that the obligations under this Section 6(a) will not apply to Confidential Information
that (i) is or becomes generally available to the public without breach of the commitments contemplated by this Section 6(a), (ii) was available to Aronin or the Management Company or its Affiliates, directors,
managers, officers, equityholders, employees or agents on a non-confidential basis prior to the date of this Agreement or (iii) is required to be disclosed by any Law or Order; provided, that as
soon as practicable prior to any such disclosure, Aronin and/or the Management Company, as applicable, shall give the Company prompt written notice of such disclosure to enable the Company to seek a protective order or otherwise preserve the
confidentiality of such information. 
 (b)    Covenant Not to Compete. For the period beginning
on the Effective Date and ending on the second anniversary of the date on which all of Aronin and the Management Company and its Affiliates (including, for the avoidance of doubt, Marshman Fund Trust II) cease to own any Stock and any other equity
interest in Holdings (the “Restricted Period”), Aronin and/or the Management Company, as applicable, will not, directly or indirectly, own, manage, operate, join, control, finance or participate in, or participate in the ownership,
management, operation, control or financing of, or be connected as an owner, investor, partner, joint venturer, director, limited liability company manager, employee, independent contractor, consultant or other agent of, any Person or enterprise
that is developing a pharmaceutical product in the sleep field, or owns, licenses, sells, or markets such a product anywhere in or with respect to the Territory. 

  
 4 

 (c)    During the Restricted Period, Aronin and the
Management Company will not, directly or indirectly: 
 i.    solicit or induce or attempt to solicit or
induce (including by recruiting, interviewing or identifying or targeting as a candidate for recruitment) any officer or personnel (whether engaged as an employee or independent contractor) of the Company (a “Business Associate”),
to terminate, restrict or hinder such Business Associate’s association with the Company or interfere in any way with the relationship between such Business Associate and the Company; provided, however, that after the termination
or expiration of this Agreement, general solicitations published in a journal, newspaper or other publication or posted on an internet job site and not specifically directed toward Business Associates will not constitute a breach of the covenants in
this Section 6(c); or 
 ii.    hire or otherwise retain the services of any
Business Associate as officer, employee, independent contractor, licensee, consultant, advisor, agent or in any other capacity, or attempt or assist anyone else to do so. 

(d)    Scope of Covenants; Equitable Relief. Aronin and the Management Company acknowledge and agree
that (i) the restrictive covenants contained in this Section 6 and the territorial, time, activity and other limitations set forth herein are commercially reasonable and do not impose a greater restraint than is
necessary to protect the goodwill and legitimate business interests of the Company and its businesses, (ii) any breach of the restrictive covenants in this Section 6 will cause irreparable injury to the Company and
that actual damages may be difficult to ascertain and would be inadequate, (iii) if any breach of any such covenant occurs, then the Company will be entitled to seek injunctive relief in addition to such other legal and equitable remedies that
may be available (without limiting the availability of legal or equitable, including injunctive, remedies under any other provisions of this Agreement) and (iv) Aronin and the Management Company hereby waive the claim or defense that an
adequate remedy at law exists for such a breach. 
 7.    Inventions. 

(a)    The Management Company agrees that all Inventions will be the sole and exclusive property of
Company. The Management Company hereby irrevocably transfers and assigns to the Company, and agrees to irrevocably transfer and assign to the Company, all right, title and interest throughout the world in and to any and all pharmaceutical products,
inventions, improvements, techniques, know-how, algorithms, processes, designs, technology, information, software, illustrations, artwork, documentation, photographs, trademarks, materials, original works of
authorship, biological or chemical specimens or samples, databases and trade secrets that the Management Company may solely or jointly make, conceive or develop or reduce to practice during the Term, that result from or arise out of the Services or
that are aided by the use of time, materials, facilities, trade secrets, or proprietary information of the Company, whether or not they are eligible for patent, copyright, mask work, trade secret, trademark or other legal protection (collectively,
the “Inventions”). Without limiting the generality of the foregoing, the Company will be the sole owner of any regulatory dossiers and regulatory filings for the Product or other products of the Company that are prepared and/or
filed by the Management Company pursuant to the Agreement. 

  
 5 

 (b)    The Management Company hereby irrevocably
transfers and assigns to the Company, and agrees to irrevocably transfer and assign to the Company, all right, title and interest throughout the world to any and all intellectual property rights in or associated with such Inventions, including
without limitation all patents, copyrights, trademark rights, trade dress rights and trade secret rights, and applications for any of the foregoing (collectively “Intellectual Property Rights”). The Management Company will promptly
make full written disclosure to the Company of all Inventions and will hold all Inventions in trust for the sole right and benefit of the Company. All copyrightable works made by the Management Company during the Term are and will be treated as
“works made for hire” to the greatest extent permitted by applicable law. At the Company’s request and expense, during and after the term of this Agreement, the Management Company will assist and cooperate with the Company in all
respects and will cause all Management Company personnel to assist and cooperate with the Company in all respects, and will execute documents and will cause all Management Company personnel to execute documents, and will take such further acts
reasonably requested by the Company to enable the Company to acquire, transfer, maintain, perfect and enforce its Intellectual Property Rights and other legal protections for the Inventions. The Management Company hereby appoints the officers of the
Company as the Management Company’s attorney-in-fact to execute documents on behalf of the Management Company for this limited purpose. 

(c)    The assignments by the Management Company to the Company of Inventions hereunder includes
(i) all rights of attribution, paternity, integrity, disclosure and withdrawal, (ii) any rights that the Management Company may have under the Visual Artists Rights Act of 1990 or similar federal, state, foreign or international laws or
treaties, and (iii) all other rights throughout the world sometimes referred to as “moral rights” (collectively “Moral Rights”). To the extent that Moral Rights cannot be assigned under applicable law, the Management
Company hereby waives such Moral Rights to the extent permitted under applicable law and consents to any and all actions of the Company that would otherwise violate such Moral Rights. 

(d)    To the extent that the Management Company owns or controls (presently or in the future) any patent
rights, copyright rights, mask work rights, trade secret rights, or any other intellectual property or proprietary rights that may block or interfere with, or may otherwise be required for, the exercise by the Company of the rights assigned to the
Company under this Section 7 (collectively, “Related Rights”), the Management Company hereby grants or will cause to be granted to the Company a non-exclusive,
royalty-free, irrevocable, perpetual, transferable, worldwide license (with the right to sublicense) to make, have made, use, offer to sell, sell, import, copy, modify, create derivative works based upon, distribute, sublicense, display, perform and
transmit any products, software, hardware, methods or materials of any kind that are covered by such Related Rights, to the extent necessary to enable the Company to exercise all of the rights assigned to the Company under this
Section 7. 
 8.    Warranties. 

(a)    No Pre-existing Obligations. The Management Company
represents and warrants that the Management Company has no pre-existing obligations or commitments 

  
 6 

 
(and will not assume or otherwise undertake any obligations or commitments) that would be in conflict or inconsistent with or that would hinder the Management Company’s performance of its
obligations under Section 1 of this Agreement. 
 (b)    Agreements with
Consultant Personnel. The Management Company represents and warrants that all Management Company personnel who perform Services are and will be bound by written agreements with the Management Company under which: (i) the Management Company
owns or is assigned exclusive ownership of all Inventions, including all Intellectual Property Rights therein; and (ii) the Management Company personnel agree to limitations on the use and disclosure of Confidential Information no less
restrictive than those provided in Section 6. 
 9.    Definitions. 

“Affiliate” means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is
under common control with such Person. As used herein, the term “control” means: (i) the power to vote at least fifty percent (50%) of the voting power of a Person, or (ii) the possession, directly or indirectly, of any other
power to direct or cause the direction of the management and policies of such a Person, whether through ownership of voting securities, by contract or otherwise. 

“A&R Certificate of Incorporation” means the Amended and Restated Certificate of Incorporation of Holdings dated as of
September 21, 2017. 
 “Board” means the board of directors of Holdings. 

“Cause” shall exist with respect to the Management Company if: 

(i)    the Management Company or Aronin has been convicted of or pleaded nolo contendere in respect
of any felony or any other crime involving fraud or dishonesty with respect to the Company or any of its Affiliates involving amounts in excess of $25,000; 

(ii)    the Management Company has substantially and repeatedly failed to perform its duties and
responsibilities under this Agreement, which failure continues for at least thirty (30) days following the Management Company’s receipt of written notice thereof specifying in reasonable detail the action or omission that constitutes such
failure; 
 (iii)    Aronin has engaged in consistent alcohol abuse or illegal drug use that interferes
with the performance of the Management Company’s duties hereunder; or 
 (iv)    the Management
Company or Aronin has engaged in any act or omission constituting willful misconduct that has caused material injury to the Company. 

“Holdings” means Harmony Biosciences II, Inc., a Delaware corporation. 

  
 7 

 “Investors” means each of the stockholders listed on Schedule A of that
certain Investors’ Rights Agreement, dated as of the Effective Date, by and among Holdings, the Investors and the Key Holders (as defined therein) (the “Investors’ Rights Agreement”). 

“IPO” means Holdings’ first underwritten public offering of its Common Stock under the Securities Act. 

“Law” means any federal, state, local, municipal, foreign, international, multinational or other constitution, statute, law,
rule, regulation, ordinance, code, principle of common law or treaty. 
 “Order” means any order, injunction, judgment,
decree, ruling, assessment or arbitration award of any government authority or arbitrator. 
 “Person” means an individual,
a partnership, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, investment fund, any other business entity and a governmental entity or any department,
agency or political subdivision thereof. 
 “Sale of Harmony” means a transaction or series of related transactions in
which an independent third Person, or an independent group of related third Persons, acquires (whether by merger, consolidation, sale, exclusive license, exclusive marketing or distribution, recapitalization, transfer, exchange or other distribution
or disposition) from stockholders of Holdings shares representing more than fifty percent (50%) of (i) the issued and outstanding shares of capital stock of Holdings or any of its subsidiaries (provided that, in the case of such sale of the
shares of capital stock of any of Holdings’ subsidiaries, the shares of capital stock of such subsidiary or subsidiaries constitute substantially all of the assets of Holdings and its subsidiaries, taken as a whole), or (ii) the assets of
Holdings and its subsidiaries, taken as a whole. 
 “Securities Act” means the Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder. 
 “Stock” means, collectively, the Series A Preferred Stock (the
“Preferred Stock”) and the Common Stock of Holdings (the “Common Stock”). 

10.    Notices. All notices and other communications hereunder shall be in writing and shall be
(a) delivered personally, (b) sent by facsimile or overnight mail, postage prepaid, or (c) sent by e-mail, with electronic, written or oral confirmation of receipt, addressed as follows (or at
such other address or number for a party as shall be specified by like notice): 
 if to the Management Company, to: 

Paragon Biosciences, LLC 

[Address] 

  
 8 

 if to the Company, to: 

Harmony Biosciences, LLC 

[Address] 
 Any such notice
shall be deemed to be delivered, given and received for all purposes as of: (i) the date so delivered, if delivered personally, (ii) upon receipt, as confirmed by a confirmation page if sent by facsimile, or by electronic, written or oral
confirmation of receipt if sent by email or (iii) on the date of receipt or refusal indicated by the overnight carrier, if sent by overnight mail, postage and charges prepaid and properly addressed. 

11.    Liability; Indemnification. 

(a)    Notwithstanding and in addition to any rights afforded the Company and any of its present or former
partners, shareholders, members, directors, officers, employees or agents (collectively, the “Company Indemnitees”), the Management Company shall indemnify and hold harmless each Company Indemnitee from and against any loss, expense
or damage payable to a third party by such Company Indemnitee as a result of any claim, action or proceeding brought against a Company Indemnitee by such third party, including any judgment, award, settlement, reasonable attorneys’ fees and
other costs or expenses incurred in connection with the defense of such claim, action or proceeding, to the extent arising primarily from (i) the material breach of this Agreement by the Management Company or (ii) any fraud, bad faith or
gross negligence of the Management Company or any Management Company Indemnitee (as defined below). 

(b)    Notwithstanding and in addition to any rights afforded the Management Company and any of its present
or former partners, shareholders, members, directors, officers, employees or agents (collectively, the “Management Company Indemnitees”), the Company shall indemnify and hold harmless each Management Company Indemnitee from and
against any loss, expense or damage payable to a third party by such Management Company Indemnitee as a result of any claim, action or proceeding brought against a Management Company Indemnitee by such third party, including any judgment, award,
settlement, reasonable attorneys’ fees and other costs or expenses incurred in connection with the defense of such claim, action or proceeding, to the extent arising from the Management Company’s performance of the Management Services;
provided, however, that Company shall have no indemnification obligations hereunder to the extent such loss, expense or damage results primarily from the material breach of this Agreement by the Management Company or fraud, bad faith
or gross negligence of the Management Company or any Management Company Indemnitee. 
 (c)    If any
Management Company Indemnitee or Company Indemnitee (each, an “Indemnitee”) learns of a third party claim for which it intends to seek indemnification hereunder, then such Indemnitee shall give prompt written notice thereof to the
indemnifying party and shall permit the indemnifying party to defend and/or settle such 

  
 9 

 
third party claim, so long as it does so diligently and in good faith; provided, that any delay in providing such notice shall not limit the rights of indemnification of such Indemnitee
under this Agreement except to the extent such delay prejudices the indemnifying party’s ability to defend such claim. If determined by the indemnifying party, any such indemnification may be paid by the indemnifying party in advance of the
final disposition of any such action, proceeding or claim upon receipt of an undertaking by or on behalf of such Indemnitee seeking advancement to repay the amount advanced should it ultimately be determined that such Indemnitee was not entitled to
be indemnified hereunder. 
 (d)    NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT TO THE
CONTRARY, (i) NEITHER PARTY SHALL HAVE ANY LIABILITY FOR CONSEQUENTIAL, PUNITIVE, INDIRECT, SPECIAL, EXEMPLARY OR INCIDENTAL DAMAGES, TO THE OTHER PARTY (INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS, REVENUES, DATA AND/OR USE), ARISING OUT OF
OR IN CONNECTION HEREWITH OR THE PERFORMANCE BY THE MANAGEMENT COMPANY OF THE SERVICES, AND (ii) IN NO EVENT SHALL THE AGGREGATE LIABILITY OF THE MANAGEMENT COMPANY UNDER THIS AGREEMENT EXCEED THE AGGREGATE AMOUNT PAID BY THE COMPANY TO THE
MANAGEMENT COMPANY UNDER THIS AGREEMENT DURING THE TWELVE (12) MONTH PERIOD IMMEDIATELY PRECEDING THE OCCURRENCE OF THE EVENT GIVING RISE TO THE ALLEGED DAMAGES. 

12.    Structural Indemnification. The Management Company hereby agrees to defend, indemnify and hold
harmless the Company against all claims, expenses, costs, damages, liabilities and losses (including attorneys’ fees, judgments, fines, excise taxes or penalties) incurred or suffered by the Company (or one or more of the Company’s
Affiliates) as arising out of or resulting from any taxes imposed upon the Company related to the treatment of any employee or service provider of the Management Company for purposes of tax reporting or tax withholdings and/or the status of any
employee of the Management Company as an employee of the Company. 
 13.    Insurance. During the
Term, the Company shall obtain and maintain at its own expense, standard directors and officers liability insurance policy (“D&O Policy”), which D&O Policy shall list each of the Management Company and Aronin as an
additional insured. At all times during the engagement of the Management Company and for a period of six (6) years thereafter, the Company shall maintain the D&O Policy in amounts not less than those in effect on the Effective Date. 

14.    Relationship of the Parties. Nothing contained herein shall be construed to place the parties
in the relationship of employer/employee, partners or joint venturers. Except as otherwise provided in this Agreement, the Company shall have no power to obligate or bind the Management Company in any manner whatsoever. The Management Company shall
not have any power to obligate or bind the Company in any manner whatsoever, other than as provided by this Agreement and pursuant to the exercise fits authority hereunder. 

15.    Non-Assignability and Delegation. This Agreement shall
not be assigned by either party hereto without the prior written consent of the other party; provided, however, that the 

  
 10 

 
consent of the Company to any assignment of this Agreement shall be subject to the authorization and approval of the Board. Notwithstanding the foregoing, Company shall be permitted, without any
requirement to obtain the Management Company’s consent, to assign this Agreement (a) in part or in its entirety to an Affiliate of the Company or (b) in its entirety to the successor to all or substantially all of the assets or
business of the Company to which this Agreement relates, whether by merger, acquisition, sale of stock, sale of assets, or otherwise. The Management Company shall perform the Management Services itself and shall not subcontract or delegate any of
its rights or obligations under this Agreement without the prior written consent of the Company following the authorization and approval of the Board. Any and all contracts with third parties relating to Wakix® or other Company products will be between the Company and the applicable third party, except to the extent that the Company agrees in writing to allow the Management Company to directly contract
with one or more third parties. Subject to the prohibitions contained in this Section 15, this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the Company and the
Management Company. 
 16.    Governing Law. This Agreement, including its existence, validity,
construction and operating effect, and the rights of each party hereto, shall be governed by and construed in accordance with the laws of the State of Illinois without giving effect to any conflicts or choice of laws provisions that would cause the
application of the domestic substantive laws of any other jurisdiction. 
 17.    Miscellaneous  

(a)    This Agreement constitutes the entire agreement between the parties hereto pertaining to the subject
matter hereof and fully supersedes any and all prior or contemporaneous agreements or understandings between the parties hereto pertaining to the subject matter hereof. 

(b)    If any provision of this Agreement as applied to any party or any circumstances is determined by an
arbitrator or any court having jurisdiction to be void, unenforceable or inoperative as a matter of law, then such provision shall be modified to the greatest extent legally possible so that the intent of this Agreement may be legally carried out.
If any one or more of the provisions contained herein, or the application thereof in any circumstances, is held void, unenforceable or inoperative as a matter of law in any respect or for any reason, then the validity, enforceability and operation
of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired or affected, it being intended that each party’s rights and privileges shall be enforceable to the fullest extent permitted by
law. 
 (c)    This Agreement may be executed in counterparts, any of which may be delivered via
facsimile, .pdf or other forms of electronic delivery, each of which shall be deemed to be an original and all of which, taken together, shall constitute one agreement. 

Signature Page Follows. 

  
 11 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date
first above written. 
  

			
	Management Company
	
	PARAGON BIOSCIENCES, LLC
		
	By:	 	 /s/ Jeffrey S. Aronin

	Name:	 	Jeffrey S. Aronin
	Title:	 	President and Secretary
	
	Company
	
	HARMONY BIOSCIENCES, LLC
		
	By:	 	 /s/ Patrick J. Morris

	Name:	 	Patrick J. Morris
	Title:	 	General Counsel
	
	Aronin solely with respect to Section 6 of this Agreement
		
	By:	 	 /s/ Jeffrey S. Aronin

	Name:	 	Jeffrey S. Aronin

  
 [Signature Page to
Management Services Agreement] 

 Schedule A 

 

	 	•	 	 Senior-level strategic and tactical guidance and support 

 

	 	•	 	 Oversight, advice and support services relating to pharma-related matters, including: 

 

	 	•	 	 Research & development and formulation 

 

	 	•	 	 Preclinical 

  

	 	•	 	 Clinical pharmacology 

  

	 	•	 	 New indication clinical development 

 

	 	•	 	 New indication project management 

 

	 	•	 	 New indication regulatory 

 

	 	•	 	 New indication quality assurance 

 

	 	•	 	 Regulatory strategy 

  

	 	•	 	 Advisory committee preparation 

 

	 	•	 	 Human resources support services 

 

	 	•	 	 Financial oversight 

  

	 	•	 	 Financial infrastructure 

 

	 	•	 	 Information technology infrastructure and technical support 

 

	 	•	 	 Merger and acquisition strategy and tactical support 

 

	 	•	 	 Oversight, advice and support services relating to finance/accounting 

 

	 	•	 	 Legal oversight, services and support 

 

	 	•	 	 Accounting, finance, and commercial servicesEX-10.14

 Exhibit 10.14 

RIGHT OF USE AGREEMENT 
 This Right of Use
Agreement (“Agreement”), effective as of November 1, 2019 (the “Effective Date”), is by and between Paragon Biosciences, LLC, a Delaware limited liability company (“Paragon”), and Harmony Biosciences, LLC, a
Delaware limited liability company (the “Portfolio Company”). 
 Recitals 

WHEREAS, Paragon and the Portfolio Company are both engaged in the Healthcare industry. 

WHEREAS, the Portfolio Company is one of Paragon’s portfolio companies. 

WHEREAS, there is benefit to both Paragon and the Portfolio Company for the Portfolio Company, together with current and future Paragon portfolio companies,
to use office space in Paragon’s Innovation Center located at 330 N. Wabash Street, Suite 3500, Chicago, Illinois 60611 (the “Paragon Innovation Center”). 

Agreement 
 In consideration of the
foregoing recitals and the covenants and fees set forth herein and subject to the Terms & Conditions attached hereto and the Portfolio Company’s Paragon Innovation Center rules and regulations as in effect during the Term
(“Paragon’s Rules & Regulations”), together with any Addenda hereto, Paragon shall grant the Portfolio Company a license to use on a non-exclusive basis, together with Paragon and other
current and future Paragon portfolio companies, one or more offices in the Paragon Innovation Center (referred to herein as the “Office”), and the facilities and services of the Paragon Innovation Center (together with the Office,
sometimes collectively referred to herein as the “accommodation”), upon and subject to the terms set forth below. 
 The basic terms of this
Agreement are as follows: 
 TERM 
 The term of this
Agreement shall commence on the Effective Date and end on December 31, 2020 (the “Initial Term”), subject to (a) early termination by either party for any or no reason on at least thirty (30) days’ prior written notice
and (b) automatic renewals for subsequent twelve (12) month periods (each, a “Renewal Term”) in the event that neither party provides written notice of non-renewal to the other party at least thirty (30) days prior to the
expiration of the Initial Term or Renewal Term, as the case may be. The “Term” of this Agreement shall mean the Initial Term and any Renewal Term, as the case may be. 

PAYMENTS 
 On or before March 1, 2020, the Portfolio
Company shall pay to Paragon one lump-sum payment of $400,000, together with interest thereon which shall accrue from the Effective Date through the 

  
 1 

 
date of payment hereunder at an interest rate of 3% per annum, compounded annually (based on a 365 day year), with respect to the Portfolio Company’s allocation of Paragon’s incremental
operating expenses incurred to develop the Paragon Innovation Center. 
 During the Term, the Portfolio Company shall pay to Paragon $20,321 per calendar
month (which amount may be increased or decreased from time to time by mutual written agreement of the parties) (the “Monthly Office Charge”), payable on or before the 15th day of each such calendar month. 

In addition, during the Term, the Portfolio Company shall pay to Paragon $3,333.33 per calendar month for the Portfolio Company’s allocated share of the
Paragon Innovation Center daily operating expenses and utilities (which amount may be increased or decreased from time to time by mutual written agreement of the parties) (the “Monthly Operating Charge”). 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

									
	PARAGON BIOSCIENCES, LLC	 		 	HARMONY BIOSCIENCES, LLC
					
	By:	  	 /s/ Patrick J. Morris
	 		 	By:	 	 /s/ John Jacobs

	Name:	  	Patrick J. Morris	 		 	Name:	 	John Jacobs
	Its:	  	EVP, Legal Affairs & GC	 		 	Its:	 	President & CEO

  
 2 

 TERMS & CONDITIONS 

 

	1.	 NATURE OF THE AGREEMENT: 

1.1.    This Agreement is the commercial equivalent of an agreement for an accommodation in a hotel. The Paragon Innovation Center remains
Paragon’s property and in Paragon’s possession and control. The Portfolio Company acknowledges that this Agreement is a license agreement and creates no tenancy interest, leasehold estate or other real property interest with respect to the
accommodation and shall not be deemed or construed in any way to create a partnership or relationship of landlord and tenant between the parties hereto. Use of workstations (offices, cubicles or other work spaces) is subject to availability and may
change at Paragon’s discretion. The Portfolio Company will not be guaranteed the same or dedicated space during the contract period. THE PORTFOLIO COMPANY HEREBY WAIVES ANY AND ALL NOTICES TO CURE (EXCEPT AS EXPRESSLY SET FORTH IN SECTION 4.1
HEREOF), VACATE OR QUIT THE OFFICE. 
 1.2.    The Agreement is personal to the Portfolio Company and cannot be transferred or assigned
to any other party, unless written request of such assignment is submitted to Paragon and Paragon agrees to such assignment, which will be at Paragon’s sole discretion, and the Portfolio Company will not permit occupancy or use of any part of
the Office or the Paragon Innovation Center by any persons other than the Portfolio Company, its agents and employees. 

1.3.    Subject to all Terms & Conditions, Paragon’s Rules & Regulations and any Exhibits or Addenda hereto,
Paragon is granting the Portfolio Company a license for the use of the accommodations specified in this this Agreement. All utilities, including any telephones and IT/data connection(s) outlined in this Agreement, shall be provided to the
accommodation without additional expense to the Portfolio Company. 
 1.4.    In the event the Paragon Innovation Center is no longer
available and Paragon is permanently unable to provide the accommodations at the Paragon Innovation Center as stated in this Agreement, this Agreement will end and the Portfolio Company will only be obligated to pay monthly fees up to the date this
Agreement ends and for the additional services the Portfolio Company has used.. 
 1.5.    Paragon can enter the Portfolio
Company’s Office at any time. 
 1.6.    The Portfolio Company, its agents, employees and invitees, agree to abide by and observe
the rules and regulations of Paragon’s lease (the “Lease”) with the owner of the building (“Landlord”) in which the Paragon Innovation Center is located (the “Building”). The Portfolio Company’s Agreement is
subordinate to the Lease and to any other agreements to which the Lease is subordinate. This Agreement terminates, if not earlier, simultaneously with the expiration or sooner termination of the Lease for any reason. The Portfolio Company does not
have any rights under the Lease (and all requests for building services shall be directed solely to Paragon), although the Portfolio Company will attorn to Landlord in such cases as may be required by the terms of the Lease or requested by Paragon
or Landlord. 
 1.7.    Paragon may assign this Agreement and the Portfolio Company agrees to accept any such assignee. Upon any such
assignment, Paragon will be discharged from all liability hereunder. 

  
 3 

 1.8.    All notices or other communications, except for service of process, must be in
writing and shall be deemed duly given if delivered in person, or by a nationally-recognized commercial delivery service. 

1.9.    This Agreement shall be interpreted under the laws of the State of Illinois, without regard to conflicts of law. THE PORTFOLIO
COMPANY HEREBY EXPRESSLY AND KNOWINGLY WAIVES ANY AND ALL RIGHT TO A JURY TRIAL IN ANY ACTION OR SUIT ARISING OUT OF THIS AGREEMENT OR THE PERFORMANCE OR NON-PERFORMANCE HEREOF. 

1.10.    The Portfolio Company must pay any reasonable and proper costs including legal fees that Paragon incurs in enforcing this
Agreement. 
 1.11.    This Agreement supersedes any prior agreement and embodies the entire agreement between the Portfolio Company and
Paragon with respect to the subject matter hereof. This Agreement is an arm’s length transaction between disinterested parties. There shall be no presumption of construction against the drafter of this Agreement. 

1.12.    The Portfolio Company and Paragon acknowledge and agree that neither Landlord, nor Landlord’s agent, are parties to this
Agreement and neither of them shall have any contractual liability or duty to the Portfolio Company by virtue of this Agreement, and that this Agreement shall not affect the rights and obligations between Paragon and Landlord. 

 

	2.	 USE AND OCCUPANCY: 

2.1.    The Portfolio Company agrees to use and occupy the Office solely for general office purposes. The Portfolio Company will only
conduct business in the name as stated on the first page of this Agreement or some other name that Paragon has previously approved in writing. 

2.2.    The Portfolio Company agrees to comply, at its expense, with all applicable laws, orders, regulations and rules, pertaining to the
use and occupancy of the Office, and the conduct of the Portfolio Company’s business. The Portfolio Company must conduct its business so as not to interfere with the use of the Paragon Innovation Center by Paragon or other Paragon portfolio
companies or their respective agents, employees or invitees, and the tenants of the Building and so as not to detract from the appearance of the Paragon Innovation Center. The Portfolio Company must comply with Paragon’s safety standards, with
Paragon’s Rules & Regulations and the Building’s rules and regulations. The Portfolio Company may not cause any nuisance or annoyance, cause the increase of insurance premiums Paragon has to pay, or cause loss or damage to Paragon
(including damage to Paragon’s reputation) or to Paragon’s Landlord. The Portfolio Company acknowledges that (a) the terms of the this Section 2.2 are a material inducement in Paragon’s execution of the Agreement and
(b) any violation by the Portfolio Company of this Section 2.2 shall constitute a material default by the Portfolio Company hereunder, entitling Paragon to terminate this Agreement without further notice or procedure. 

2.3.    The Portfolio Company agrees to pay promptly (i) all sales, use, excise, consumption and any other taxes and license fees
which the Portfolio Company is required to pay to any governmental authority (and, at Paragon’s request, will provide evidence of such payment) and (ii) any taxes paid by Paragon to any governmental authority that are attributable to this
Agreement, or the accommodations provided hereunder, including, without limitation, any gross receipts, rent and occupancy taxes, or tangible personal property taxes. 

  
 4 

 2.4.    The Portfolio Company shall make no alterations or modifications in or to the
Office, including, without limitation, affixing any signs or postings, and any door locks, without Paragon’s prior written consent (which Paragon may grant or withhold in its sole discretion). In the event that alterations or modifications are
made without Paragon’s prior written consent, Paragon may, at Paragon’s option, correct or remove the same at the Portfolio Company’s sole cost and expense. 

2.5.    All keys and entry cards remain Paragon’s property and shall not be duplicated or transferred to third parties. The loss of
keys or cards must immediately be reported to Paragon. The Portfolio Company will be responsible for the cost of lost keys or cards as well as the cost of changing locks. 

2.6.    The Portfolio Company may not have any advertising of any type using the address of the Paragon Innovation Center without
Paragon’s prior written consent (which Paragon may grant or withhold in its sole discretion). Use of the address on business cards, websites, and other standard business practices are acceptable without written consent. 

2.7.    The Portfolio Company shall not, without Paragon’s prior written consent (which Paragon may grant or withhold in its sole
discretion), store or operate any computer equipment (except personal computer equipment) or any other large business machines, reproduction equipment, heating equipment, stove, mechanical amplification equipment, vending or coin-operated machines,
refrigerator or coffee equipment. 
 2.8.    The Portfolio Company may not install any cabling, IT or telecom connections without
Paragon’s prior written consent (which Paragon may grant or withhold in its sole discretion). As a condition of Paragon’s consent, the Portfolio Company will permit Paragon to oversee any installations (for example, IT or electrical
systems) to verify that such installations do not interfere with the use of the Paragon Innovation Center by Paragon, other the Paragon portfolio companies or Landlord. Paragon’s consent may also be conditioned upon the payment of additional
fees for installation and/or usage of such cabling, and/or the requirement that the Portfolio Company remove the cabling, etc. All cables in the ceiling or walls of the Paragon Innovation Center shall become Paragon’s property. 

2.9.    The electrical current shall be used for ordinary lighting, powering personal computer equipment and small appliances only. If the
Portfolio Company requires any special installation or wiring for electrical use, telephone equipment or otherwise, such wiring shall be done with Paragon’s prior written approval, at the Portfolio Company’s sole expense by a company
approved by Paragon. The Portfolio Company shall not install or operate any equipment or machinery that requires a separate electrical circuit or consumes higher than normal and reasonable quantities of electricity. 

 

	3.	 LATE PAYMENTS 

3.1.    Paragon may charge the Portfolio Company a late payment charge equal to 10% of the arrearage with respect to any payment that is
due and payable under this Agreement but is not paid when due. 

  
 5 

	4.	 DEFAULT AND TERMINATION: 

4.1.    Paragon may terminate this Agreement immediately by giving the Portfolio Company notice and without need to follow any additional
procedures if: (a) the Portfolio Company becomes insolvent, bankrupt, goes into liquidation or becomes unable to pay its debts as they become due, or (b) the Portfolio Company is in breach of one of the Portfolio Company’s obligations
under this Agreement which cannot be cured or which Paragon has given the Portfolio Company notice to cure and which the Portfolio Company has failed to cure within thirty (30) days after written notice of such breach. 

4.2.    Paragon shall have the right to terminate the Agreement immediately if the Portfolio Company is or becomes (i) identified on
the Specially Designated Nationals and Blocked Person List maintained by the U.S. Department of the Treasury Office of Foreign Assets Control or any similar list or (ii) a person, entity, or government with whom a citizen of the United States
is prohibited from engaging in transactions by any trade embargo, economic sanction, or other prohibition of United States law, regulation or Executive order of the President of the United States. 

4.3.    If Paragon terminates the Agreement for any of the reasons described in the immediately preceding paragraphs, the Portfolio
Company shall remain responsible for its outstanding obligations under this Agreement. The Portfolio Company may, in addition to any other obligations contained herein, be required to pay the amounts set forth in this Agreement for the remainder of
the Term if Paragon had not so terminated this Agreement, or for a further period of three months, whichever is longer. In such event, Paragon may also take possession of the Office. 

4.4.    A waiver by either Paragon or the Portfolio Company of a breach (or series of breaches) of any covenant or obligation under this
Agreement of the other party shall not be construed to be a waiver of any other covenant or obligation or of any subsequent breach of the same covenant or obligation. Notwithstanding the Paragon’s reservation of any particular remedy hereunder,
Paragon hereby reserves each and every remedy available at law or in equity in the event of a breach by the Portfolio Company hereunder. 

4.5.    Upon the expiration or termination of the Agreement, the Portfolio Company’s right to occupy the Office and use the Paragon
Innovation Center is revoked and the Portfolio Company will remove all of its property and return the Office and furniture in the same condition in which it was delivered to the Portfolio Company, subject to reasonable wear and tear. Any personal
property left in the Office will be considered abandoned and Paragon may dispose of it without any liability to the Portfolio Company. All telephone and facsimile numbers are Paragon’s property and cannot be transferred to the Portfolio Company
at the expiration or termination of the Agreement. 
 4.6.    For a period of 30 days after the expiration or termination of this
Agreement, Paragon will redirect the Portfolio Company’s mail upon receipt to an address provided in writing by the Portfolio Company at no charge and shall place a recorded message on the Portfolio Company’s telephone line providing the
Portfolio Company’s new telephone number, as provided by the Portfolio Company in writing to Paragon, at no charge. Thereafter, Paragon shall have no obligation whatsoever to forward mail to the Portfolio Company or provide phone service. 

  
 6 

 4.7.    If the Portfolio Company continues to occupy the Office after the Term of this
Agreement has ended, the Portfolio Company will be responsible for any loss, claim or liability Paragon incur as a result of the Portfolio Company’s failure to vacate on time. Paragon may, at Paragon’s discretion, permit the Portfolio
Company an extension subject to a surcharge on the Monthly Office Charge and the Monthly Operating Charge. 
 4.8.    If the Paragon
Innovation Center is made unusable in whole or in part by fire or other casualty or condemnation, Paragon may, at Paragon’s option, either terminate this Agreement upon notice to the Portfolio Company, or repair the Paragon Innovation Center.

  

	5.	 LIABILITY: 

5.1.    To the maximum extent permitted by applicable law, Paragon is not liable to the Portfolio Company in respect of any loss or damage
the Portfolio Company suffers in connection with this Agreement or in connection with the services or the accommodations. Without limitation of the foregoing, Paragon is not liable for any loss or damage as a result of Paragon’s failure to
provide any service or accommodation under this Agreement as a result of mechanical breakdown, strike, termination of Paragon’s Lease, or otherwise. 

5.2.    PARAGON WILL NOT UNDER ANY CIRCUMSTANCES HAVE ANY LIABILITY FOR LOSS OF BUSINESS, LOSS OF PROFITS, LOSS OF ANTICIPATED SAVINGS,
LOSS OF OR DAMAGE TO DATA OR ANY CONSEQUENTIAL DAMAGES. 
 5.3.    The Portfolio Company assumes all risk of loss with respect to the
Portfolio Company’s personal property and the Portfolio Company’s agents, employees and invitees within the Paragon Innovation Center or the Building. 

5.4.    To the extent that the party sustaining a loss by fire or other casualty to its property is compensated by insurance, Paragon and
the Portfolio Company will each waive all rights of recovery against the other party and no third party shall have any right of recovery. 

5.5.    Notwithstanding any term to the contrary, Paragon shall not be held liable to the Portfolio Company under this Agreement if
Paragon is prevented from, or delayed in, performing Paragon’s obligations under this Agreement or from carrying on Paragon’s business by acts, events, omission or accidents beyond Paragon’s reasonable control, including (without
limitation): strikes, failure of a utility service or network; act of God, war, riot, civil commotion, disease or quarantine restrictions in compliance with any law or governmental rule, regulation or direction, accident, fire, floor or storm or
default of suppliers or subcontractors. Paragon’s obligation to perform its obligations under this Agreement shall be suspended during the period required to remove such force majeure event. 

5.6.    To the fullest extent permitted by law, the Portfolio Company agrees to hold Paragon and its other portfolio companies and their
respective agents, employees, contractors, officers, directors and Landlord harmless from and against any and all claims of loss, costs, liability and expense, including reasonable attorneys’ fees and disbursements (the “Claims”),
arising from or alleged to arise from (a) any default by the Portfolio Company hereunder, (b) the use or occupancy of the Paragon Innovation Center by the Portfolio Company or any person claiming under the Portfolio Company, or
(c) the Portfolio Company’s negligence or the negligence of the Portfolio Company’s agents, employees, contractors, officers or directors. 

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]